| Introduction |
|
iii | (2) |
|
|
|
|
|
| Preface |
|
v | (2) |
| Contributors |
|
vii | |
| Part One Basic Science |
|
3 | (112) |
|
1. Hormonal Changes During Normal Pregnancy and Their Consequences |
|
|
3 | (24) |
|
|
|
|
|
|
|
|
3 | (1) |
|
|
|
4 | (3) |
|
|
|
7 | (4) |
|
|
|
11 | (1) |
|
V. Cortisol and Deoxycorticosterone |
|
|
12 | (1) |
|
|
|
13 | (2) |
|
VII. Placental Growth Hormones |
|
|
15 | (2) |
|
|
|
17 | (1) |
|
|
|
17 | (1) |
|
|
|
17 | (1) |
|
|
|
18 | (1) |
|
|
|
19 | (8) |
|
2. Fetal Oxygenation, Acid-Base Balance, and Assessment of Well-Being in the Pregnancy Complicated by Asthma or Anaphylaxis |
|
|
27 | (30) |
|
|
|
|
|
|
|
|
|
|
|
|
|
27 | (1) |
|
II. Respiratory Gas Exchange |
|
|
28 | (10) |
|
III. Uteroplacental-Fetal Oxygen Utilization |
|
|
38 | (1) |
|
IV. Uteroplacental and Fetal Blood Flow |
|
|
39 | (2) |
|
V. Relation of Alterations of Maternal Oxygenation to Fetal Oxygenation and Acid-Base Status |
|
|
41 | (1) |
|
VI. Effect of Anaphylaxis on the Fetus |
|
|
41 | (1) |
|
|
|
42 | (7) |
|
VIII. Obstetrical Management of the Pregnant Asthmatic Patient |
|
|
49 | (3) |
|
|
|
52 | (5) |
|
3. Pulmonary Function During Pregnancy |
|
|
57 | (16) |
|
|
|
|
|
|
|
|
57 | (1) |
|
|
|
58 | (3) |
|
III. Spirometry and Airflow Mechanics |
|
|
61 | (1) |
|
IV. Chest Wall and Abdominal Mechanics |
|
|
61 | (1) |
|
V. Ventilation and Gas Exchange |
|
|
62 | (3) |
|
VI. Diffusing Capacity for Carbon Monoxide |
|
|
65 | (1) |
|
VII. Dyspnea in Pregnancy |
|
|
65 | (1) |
|
VIII. Pulmonary Function in Disease States During Pregnancy |
|
|
66 | (1) |
|
|
|
67 | (6) |
|
4. Maternal Immune Function During Pregnancy |
|
|
73 | (28) |
|
|
|
|
|
|
|
|
73 | (1) |
|
|
|
74 | (5) |
|
III. Cell-Mediated Immunity |
|
|
79 | (10) |
|
|
|
89 | (1) |
|
|
|
90 | (11) |
|
5. The Immunology of Pregnancy: The Fetus as Allograft |
|
|
101 | (14) |
|
|
|
|
|
|
|
|
101 | (2) |
|
II. The Materno-Fetal Interface |
|
|
103 | (1) |
|
III. Is the Uterus an "Immunologically Privileged Site?" |
|
|
103 | (1) |
|
IV. HLA Expression on the Trophoblast |
|
|
104 | (2) |
|
V. Other Antigens at the Materno-Fetal Interface |
|
|
106 | (1) |
|
VI. Cells in Placental Tissue |
|
|
106 | (1) |
|
|
|
107 | (1) |
|
VIII. Cellular Traffic Across the Feto-Maternal Interface |
|
|
108 | (1) |
|
|
|
108 | (1) |
|
X. Immunoglobulin Transfer to the Fetus |
|
|
109 | (1) |
|
XI. Maternal Immunological Reactions to the Fetus |
|
|
109 | (2) |
|
|
|
111 | (1) |
|
|
|
111 | (4) |
| Part Two General Therapeutics |
|
115 | (146) |
|
6. Psychological Changes During Pregnancy: Implications for Medical Care |
|
|
117 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
117 | (1) |
|
|
|
118 | (2) |
|
|
|
120 | (2) |
|
IV. Mood Changes During Pregnancy |
|
|
122 | (2) |
|
|
|
124 | (1) |
|
|
|
125 | (4) |
|
VII. Implications for Medical Care |
|
|
129 | (3) |
|
|
|
132 | (1) |
|
|
|
133 | (4) |
|
7. Use of Medication During Pregnancy and Lactation: General Considerations |
|
|
137 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
137 | (5) |
|
II. Developmental Toxicity of Drugs |
|
|
142 | (1) |
|
III. Principles of Teratogenesis |
|
|
143 | (5) |
|
IV. Pharmacokinetic Alterations During Pregnancy |
|
|
148 | (3) |
|
|
|
151 | (1) |
|
|
|
152 | (2) |
|
|
|
154 | (3) |
|
8. Pregnancy Effects of Specific Medications Used to Treat Asthma and Immunological Diseases |
|
|
157 | (72) |
|
|
|
|
|
|
|
|
|
|
|
I. Developmental Toxicology |
|
|
158 | (1) |
|
II. Elements of Causation |
|
|
159 | (4) |
|
III. Using Experimental Animal Data |
|
|
163 | (2) |
|
IV. Case Reports and Human Epidemiologic Studies |
|
|
165 | (1) |
|
|
|
166 | (7) |
|
|
|
173 | (2) |
|
|
|
175 | (10) |
|
VIII. Mast Cell Stabilizers |
|
|
185 | (1) |
|
|
|
185 | (3) |
|
|
|
188 | (1) |
|
|
|
189 | (6) |
|
XII. Expectorants and Antitussives |
|
|
195 | (3) |
|
XIII. Desensitization ("Allergy Shots") |
|
|
198 | (1) |
|
|
|
198 | (1) |
|
XV. Analgesics/Antipyretics |
|
|
198 | (3) |
|
|
|
201 | (1) |
|
|
|
201 | (28) |
|
9. Medical/Legal Aspects of Prescribing During Pregnancy |
|
|
229 | (32) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
229 | (1) |
|
II. Characterizing a Legal Action on Behalf of a Fetus |
|
|
230 | (2) |
|
III. Food and Drug Administration Regulation |
|
|
232 | (2) |
|
IV. Responsibility to the Fetus |
|
|
234 | (3) |
|
V. Lessons from Litigation |
|
|
237 | (2) |
|
VI. Legal Standards for Causation |
|
|
239 | (6) |
|
VII. Proven, Possible, and Unlikely Teratogens |
|
|
245 | (3) |
|
VIII. Prescribing During Pregnancy |
|
|
248 | (5) |
|
|
|
253 | (1) |
|
|
|
253 | (8) |
| Part Three Allergic Diseases |
|
261 | (126) |
|
10. Allergy Diagnosis, Environmental Control, and Immunotherapy During Pregnancy |
|
|
263 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
263 | (1) |
|
II. Allergy Diagnosis in Pregnancy |
|
|
264 | (2) |
|
III. Environmental Control of Asthma |
|
|
266 | (7) |
|
IV. Allergy Immunotherapy |
|
|
273 | (2) |
|
|
|
275 | (1) |
|
|
|
275 | (4) |
|
11. The Diagnosis and Treatment of Rhinosinusitis During Pregnancy and Lactation |
|
|
279 | (36) |
|
|
|
|
|
|
|
|
279 | (1) |
|
II. Nasal Physiology in Pregnancy |
|
|
280 | (2) |
|
III. Nasal Pathophysiology During the Childbearing Years |
|
|
282 | (2) |
|
|
|
284 | (6) |
|
V. Pharmacological Treatment of Rhinitis |
|
|
290 | (7) |
|
VI. Immunological Management |
|
|
297 | (1) |
|
VII. Treatment of Sinusitis |
|
|
298 | (7) |
|
|
|
305 | (1) |
|
|
|
306 | (1) |
|
|
|
307 | (8) |
|
12. Anaphylaxis in Pregnancy |
|
|
315 | (16) |
|
|
|
|
|
|
|
|
315 | (1) |
|
|
|
315 | (1) |
|
|
|
316 | (1) |
|
IV. Etiological Mechanisms |
|
|
316 | (2) |
|
V. Clinical and Pathophysiological Findings |
|
|
318 | (1) |
|
VI. Pathological and Laboratory Manifestations of Anaphylaxis |
|
|
319 | (1) |
|
VII. Diagnosis and Differential Diagnosis of Anaphylaxis |
|
|
320 | (1) |
|
VIII. Pathogenic Mechanisms in Anaphylaxis |
|
|
321 | (1) |
|
IX. Considerations in Pregnancy |
|
|
322 | (1) |
|
X. Management of the Patient with Anaphylaxis |
|
|
323 | (3) |
|
|
|
326 | (1) |
|
|
|
327 | (1) |
|
|
|
328 | (3) |
|
13. Cutaneous Diseases During Pregnancy |
|
|
331 | (36) |
|
|
|
|
|
|
|
|
|
|
|
|
|
331 | (1) |
|
II. Cutaneous Changes in Pregnancy |
|
|
332 | (3) |
|
III. Pruritus: General Aspects |
|
|
335 | (8) |
|
IV. Pregnancy-Related Dermatoses |
|
|
343 | (4) |
|
V. Urticaria and Angioedema |
|
|
347 | (3) |
|
VI. Hereditary Angioedema |
|
|
350 | (6) |
|
|
|
356 | (3) |
|
VIII. Miscellaneous Cutaneous Immunological Disorders |
|
|
359 | (3) |
|
|
|
362 | (5) |
|
14. Immunologically Mediated Adverse Drug Reactions in Pregnancy |
|
|
367 | (20) |
|
|
|
|
|
|
|
|
367 | (2) |
|
|
|
369 | (1) |
|
III. Treatment of Specific Reactions |
|
|
370 | (7) |
|
|
|
377 | (6) |
|
|
|
383 | (4) |
| Part Four Asthma |
|
387 | (112) |
|
15. Effects of Asthma on Pregnancy and Labor |
|
|
389 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
389 | (1) |
|
II. Clinical Course of Pregnancy Complicated by Asthma |
|
|
390 | (8) |
|
|
|
398 | (1) |
|
|
|
398 | (3) |
|
16. Effect of Pregnancy on Asthma: A Systematic Review and Meta-Analysis |
|
|
401 | (28) |
|
|
|
|
|
|
|
|
|
|
|
|
|
401 | (1) |
|
II. Evaluation of an Intervention |
|
|
402 | (1) |
|
|
|
402 | (5) |
|
IV. Loss to Follow-Up and Withdrawals |
|
|
407 | (1) |
|
|
|
408 | (2) |
|
|
|
410 | (2) |
|
VII. Other Factors Affecting Asthma Severity During Pregnancy |
|
|
412 | (2) |
|
|
|
414 | (8) |
|
|
|
422 | (2) |
|
|
|
424 | (1) |
|
|
|
425 | (4) |
|
17. Diagnosis and Differential Diagnosis of Bronchial Asthma in Pregnancy |
|
|
429 | (16) |
|
|
|
|
|
|
|
|
429 | (1) |
|
|
|
430 | (1) |
|
III. Pathology and Pathophysiology |
|
|
430 | (2) |
|
|
|
432 | (4) |
|
V. Differential Diagnosis |
|
|
436 | (5) |
|
|
|
441 | (1) |
|
|
|
441 | (4) |
|
18. The Medical Management of Asthma During Pregnancy |
|
|
445 | (24) |
|
|
|
|
|
|
|
|
445 | (1) |
|
II. Asthma: General Concepts |
|
|
446 | (2) |
|
III. Gestational Asthma Management |
|
|
448 | (14) |
|
|
|
462 | (7) |
|
19. Prevention and Treatment of Severe Asthma During Pregnancy |
|
|
469 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
469 | (1) |
|
II. Recent Advances in Asthma |
|
|
470 | (2) |
|
|
|
472 | (1) |
|
IV. Physiological Changes During Gestation |
|
|
473 | (1) |
|
V. Classification of Asthma Severity During Gestation |
|
|
474 | (1) |
|
VI. Special Considerations in Asthma Management |
|
|
475 | (2) |
|
|
|
477 | (5) |
|
|
|
482 | (5) |
|
20. The Obstetrical Management of Pregnant Asthmatics |
|
|
487 | (12) |
|
|
|
|
|
|
|
|
487 | (2) |
|
|
|
489 | (1) |
|
III. Antenatal Management |
|
|
490 | (3) |
|
IV. Labor and Delivery Management |
|
|
493 | (2) |
|
|
|
495 | (1) |
|
|
|
495 | (4) |
| Part Five Immunological Diseases |
|
499 | (154) |
|
21. Systemic Lupus Erythematosus and Pregnancy |
|
|
501 | (22) |
|
|
|
|
|
|
I. Definition of Systemic Lupus Erythematosus |
|
|
501 | (1) |
|
II. Effects of SLE on Pregnancy |
|
|
502 | (6) |
|
III. Effects of Pregnancy on SLE |
|
|
508 | (1) |
|
IV. Potential Effects of Specific Treatments on Pregnancy |
|
|
509 | (2) |
|
V. Optimal Gestational Management |
|
|
511 | (2) |
|
|
|
513 | (1) |
|
|
|
513 | (1) |
|
|
|
514 | (9) |
|
22. Rheumatoid Arthritis and Other Arthropathies During Pregnancy |
|
|
523 | (28) |
|
|
|
|
|
|
|
|
|
|
|
|
|
523 | (1) |
|
|
|
523 | (16) |
|
III. Juvenile Chronic Arthritis and Adult Still's Disease |
|
|
539 | (2) |
|
IV. Spondyloarthropathies |
|
|
541 | (1) |
|
V. Summary and Conclusions |
|
|
541 | (2) |
|
|
|
543 | (8) |
|
23. "Other" Autoimmune Diseases in Pregnancy |
|
|
551 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
551 | (1) |
|
|
|
552 | (1) |
|
|
|
553 | (2) |
|
|
|
555 | (1) |
|
V. Wegener's Granulomatosis |
|
|
555 | (1) |
|
|
|
556 | (1) |
|
VII. Autoimmune Thrombocytopenic Purpura |
|
|
556 | (1) |
|
VIII. Autoimmune Hemolytic Anemia |
|
|
557 | (1) |
|
|
|
558 | (1) |
|
X. Hashimoto's Thyroiditis |
|
|
559 | (1) |
|
XI. Thyroid Autoimmunity Without Overt Disease |
|
|
559 | (1) |
|
|
|
560 | (1) |
|
XIII. Myasthenia Gravis (MG) |
|
|
561 | (1) |
|
XIV. Pemphigoid Gestationis (PG) |
|
|
561 | (1) |
|
|
|
562 | (1) |
|
XVI. Dermatomyositis/Polymyositis |
|
|
562 | (1) |
|
|
|
563 | (1) |
|
|
|
564 | (7) |
|
24. Human Immunodeficiency Virus Infection in Pregnancy |
|
|
571 | (34) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
I. Epidemiology and History |
|
|
571 | (1) |
|
|
|
572 | (3) |
|
III. Laboratory Diagnosis |
|
|
575 | (1) |
|
IV. Risk Factors for Transmission |
|
|
575 | (6) |
|
V. Screening, Counselling, and Testing |
|
|
581 | (1) |
|
VI. Treatment with Zidovudine to Prevent Mother-to-Child Transmission |
|
|
582 | (2) |
|
VII. Other Therapies for HIV Infection |
|
|
584 | (1) |
|
|
|
584 | (2) |
|
IX. Neonatal/Infant Outcome |
|
|
586 | (1) |
|
X. Principles of Prenatal Care |
|
|
587 | (2) |
|
XI. Future Considerations |
|
|
589 | (2) |
|
|
|
591 | (1) |
|
|
|
591 | (14) |
|
25. Immune Deficiency During Pregnancy |
|
|
605 | (34) |
|
|
|
|
|
|
|
|
605 | (1) |
|
II. Prevalence of Primary Immunodeficiency Disorders |
|
|
606 | (1) |
|
III. Clinical B-Lymphocyte Disorders |
|
|
606 | (7) |
|
IV. Pregnancy and Clinical B-Lymphocyte Disorders |
|
|
613 | (4) |
|
V. Complement Deficiencies |
|
|
617 | (8) |
|
VI. Granulocyte Disorders |
|
|
625 | (2) |
|
VII. Pregnancy and Granulocyte Disorders |
|
|
627 | (3) |
|
|
|
630 | (9) |
|
26. Immunological Causes of Fetal Loss |
|
|
639 | (14) |
|
|
|
|
|
|
|
|
639 | (1) |
|
II. Frequency of Spontaneous Pregnancy Loss |
|
|
640 | (1) |
|
III. Definitions of Recurrent Spontaneous Abortion |
|
|
640 | (1) |
|
IV. Causes of Recurrent Spontaneous Abortion |
|
|
641 | (1) |
|
V. Immunological Causes of Recurrent Fetal Loss |
|
|
641 | (2) |
|
VI. Maternal Immune Responses and RSAb |
|
|
643 | (2) |
|
VII. RSAb and Sharing of MHC Antigens |
|
|
645 | (4) |
|
|
|
649 | (1) |
|
|
|
650 | (3) |
| Part Six Development/Prevention of Allergic Diseases in Infancy |
|
653 | (160) |
|
27. The Genetic Basis of Asthma and Allergic Disease |
|
|
655 | (22) |
|
|
|
|
|
|
|
|
655 | (1) |
|
II. Asthma and Atopy Phenotypes |
|
|
656 | (1) |
|
III. Factors Confounding Genetic Studies of Atopy |
|
|
657 | (1) |
|
IV. The Inheritance of Atopy |
|
|
658 | (3) |
|
|
|
661 | (1) |
|
VI. Genes Influencing Asthma and Atopy |
|
|
661 | (7) |
|
VII. Whole-Genome Screens for Atopy and Asthma |
|
|
668 | (1) |
|
VIII. Genes and Environment |
|
|
669 | (1) |
|
|
|
670 | (1) |
|
|
|
670 | (7) |
|
28. Risk Factors in the Development of Allergy |
|
|
677 | (26) |
|
|
|
|
|
|
|
|
|
|
|
|
|
677 | (1) |
|
|
|
678 | (2) |
|
III. Immunological Aspects |
|
|
680 | (3) |
|
|
|
683 | (3) |
|
|
|
686 | (2) |
|
VI. Exposure to Inhalant Allergens |
|
|
688 | (1) |
|
VII. Non-Specific Environmental Factors |
|
|
689 | (6) |
|
|
|
695 | (1) |
|
|
|
695 | (8) |
|
29. The Natural History of Allergic Disease and Asthma in Childhood |
|
|
703 | (58) |
|
|
|
|
|
|
|
|
703 | (1) |
|
II. The Natural History of Atopy and Asthma in Early Childhood |
|
|
704 | (7) |
|
III. Risk Factors for the Development of Allergic Disease/Asthma |
|
|
711 | (7) |
|
IV. Asthma: Retrospective Studies |
|
|
718 | (2) |
|
V. Asthma: Prospective Studies |
|
|
720 | (5) |
|
VI. Risk Factors for the Persistence of Asthma |
|
|
725 | (17) |
|
VII. Persistence of Atopic Dermatitis |
|
|
742 | (2) |
|
VIII. Persistence of Chronic Urticaria |
|
|
744 | (1) |
|
IX. Persistence of Food Allergy and Intolerance |
|
|
744 | (4) |
|
|
|
748 | (2) |
|
|
|
750 | (11) |
|
30. Prevention of Allergic Disease in Infancy |
|
|
761 | (52) |
|
|
|
|
|
|
I. Overview of Allergy Prevention |
|
|
761 | (3) |
|
II. Primary Prevention of Allergy |
|
|
764 | (17) |
|
III. Secondary Prevention of Allergy |
|
|
781 | (4) |
|
IV. Tertiary Allergy Prevention |
|
|
785 | (7) |
|
V. Future of Allergy Prevention |
|
|
792 | (2) |
|
VI. Implications and Recommendations for the Prevention of Atopy |
|
|
794 | (1) |
|
Appendix I: Southern California Permanente Medical Group Allergy Department |
|
|
795 | (3) |
|
Appendix II: Representative Potentially Allergenic Foods: Identification and Avoidance |
|
|
798 | (3) |
|
|
|
801 | (12) |
| Part Seven Allergic and Immunological Diseases During Infancy |
|
813 | (178) |
|
|
|
815 | (44) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
815 | (1) |
|
|
|
816 | (7) |
|
III. An Approach to the Differential Diagnosis of Wheeze in Infancy |
|
|
823 | (2) |
|
|
|
825 | (18) |
|
V. An Approach to Treatment of the Individual Patient |
|
|
843 | (7) |
|
|
|
850 | (9) |
|
32. Food Hypersensitivity in Infancy |
|
|
859 | (40) |
|
|
|
|
|
|
|
|
|
|
|
I. Introduction and Definition of Terms |
|
|
859 | (1) |
|
|
|
860 | (2) |
|
III. Clinical Presentation of Food Hypersensitivity |
|
|
862 | (11) |
|
IV. Pathogenesis and Immunology |
|
|
873 | (5) |
|
|
|
878 | (3) |
|
|
|
881 | (2) |
|
VII. Natural History and Prognosis |
|
|
883 | (2) |
|
VIII. Vaccine Administration in Egg-Hypersensitive Children |
|
|
885 | (2) |
|
IX. Unproved Diagnostic and Therapeutic Practices |
|
|
887 | (1) |
|
|
|
888 | (2) |
|
|
|
890 | (9) |
|
33. Atopic Dermatitis and Other Immunological Dermatoses of Infancy |
|
|
899 | (24) |
|
|
|
|
|
|
|
|
899 | (15) |
|
|
|
914 | (1) |
|
III. Hereditary Angioedema |
|
|
915 | (2) |
|
|
|
917 | (1) |
|
|
|
918 | (5) |
|
34. Immunobiology of the Neonate and an Overview of Immune Deficiencies in the Neonatal Period |
|
|
923 | (68) |
|
|
|
|
|
|
|
|
|
|
|
I. Immunobiology of the Neonate |
|
|
923 | (27) |
|
II. Immunodeficiency Diseases Presenting in Infancy |
|
|
950 | (20) |
|
|
|
970 | (21) |
| Author Index |
|
991 | (100) |
| Subject Index |
|
1091 | |